BRIEF-Amgen says FDA issues complete response letter for NDA for Parsabiv
August 24, 2016 at 18:17 PM EDT
* Amgen provides update on status of Parsabiv(Etelcalcetide) New Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA)
